A TRPV4 antagonist, GSK2798745, is currently being administered to patients in a phase II clinical trial for treatment of congestive heart failure-induced pulmonary edema (NTC02497937) (Stewart et al., 2020). This evidence concerns the gene TRPV4 and pulmonary edema.